Translating Animal Models of Ischemic Stroke to the Human Condition

Matur, Abhijith V.; Candelario‐Jalil, Eduardo; Paul, Surojit; Karamyan, Vardan T.; Lee, Jessica D.; Pennypacker, Keith R.; Fraser, Justin F.

doi:10.1007/s12975-022-01082-9

Cited by 6 publications

(6 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(6) Subjects who have used specific medications, including anti-itch drugs, sex hormones, anti-depressants, immunomodulation drugs, or exfoliating agents. (7) Enforcing strict enrollment protocols in the stroke study. Fourth, equipment interference need to be prevented.…”

Section: Measurement Of the Af In Human Subjectsmentioning

confidence: 99%

“…There are several causes of the high mortality of stroke patients: First, there are significant limitations in the diagnostic and therapeutic capacity for stroke patients: Due to a limited therapeutic window and the potential for toxic side effects [4], only a small fraction of AIS patients are eligible for treatment with recombinant tissue-type plasminogen activator (r-tPA), which is the sole FDA-approved drug for managing ischemic stroke [5,6]; second, over the past few decades, clinical trials aimed at developing effective stroke treatment drugs have yielded limited success [7,8]; and third, the critical roles played by MRI and CT imaging equipment in stroke diagnosis [9,10] are hindered by deficiencies in many regions across the world [11][12][13].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Green autofluorescence of the skin and fingernails is a novel biomarker for evaluating the risk for developing acute ischemic stroke

Tao,

Yu,

Zhang

et al. 2024

Journal of Biophotonics

View full text Add to dashboard Cite

The only existing approach for assessing the risk of developing acute ischemic stroke (AIS) necessitates that individuals possess a strong understanding of their health status. Our research gathered compelling evidence in favor of our hypothesis, suggesting that the likelihood of developing AIS can be assessed by analyzing the green autofluorescence (AF) of the skin and fingernails. Utilizing machine learning‐based analyses of AF images, we found that the area under the curve (AUC) for distinguishing subjects with three risk factors from those with zero, one, or two risk factors was 0.79, 0.76, and 0.75, respectively. Our research has revealed that green AF serves as an innovative biomarker for assessing the risk of developing AIS. Our method is objective, non‐invasive, efficient, and economic, which shows great promise to boost a technology for screening natural populations for risk of developing AIS.

show abstract

Section: Measurement Of the Af In Human Subjectsmentioning

confidence: 99%

mentioning

confidence: 99%

Green autofluorescence of the skin and fingernails is a novel biomarker for evaluating the risk for developing acute ischemic stroke

Tao,

Yu,

Zhang

et al. 2024

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…Due to its very limited therapeutic window and toxic side effects, only a small percentage of acute ischemic stroke (AIS) patients can be treated by the drug (Peña et al 2017 ). During the last three decades, a number of clinical trials on the drugs for treating stroke have failed (Kaur et al 2013 ; Matur et al 2022 ). These pieces of information have indicated that human being is still far from conquering major diseases, which also indicates the critical significance of applying novel and revolutionary approaches to prevent, diagnose and treat diseases.…”

Section: Significance Of Phenomic Studies On Diseasesmentioning

confidence: 99%

Phenomic Studies on Diseases: Potential and Challenges

Ying

2023

Phenomics

View full text Add to dashboard Cite

The rapid development of such research field as multi-omics and artificial intelligence (AI) has made it possible to acquire and analyze the multi-dimensional big data of human phenomes. Increasing evidence has indicated that phenomics can provide a revolutionary strategy and approach for discovering new risk factors, diagnostic biomarkers and precision therapies of diseases, which holds profound advantages over conventional approaches for realizing precision medicine: first, the big data of patients' phenomes can provide remarkably richer information than that of the genomes; second, phenomic studies on diseases may expose the correlations among cross-scale and multi-dimensional phenomic parameters as well as the mechanisms underlying the correlations; and third, phenomics-based studies are big data-driven studies, which can significantly enhance the possibility and efficiency for generating novel discoveries. However, phenomic studies on human diseases are still in early developmental stage, which are facing multiple major challenges and tasks: first, there is significant deficiency in analytical and modeling approaches for analyzing the multi-dimensional data of human phenomes; second, it is crucial to establish universal standards for acquirement and management of phenomic data of patients; third, new methods and devices for acquirement of phenomic data of patients under clinical settings should be developed; fourth, it is of significance to establish the regulatory and ethical guidelines for phenomic studies on diseases; and fifth, it is important to develop effective international cooperation. It is expected that phenomic studies on diseases would profoundly and comprehensively enhance our capacity in prevention, diagnosis and treatment of diseases.

show abstract

“…[21][22][23][24] Reasons for poor bench-to-bedside translation have included varying routes of administration (intravenous, intraperitoneal, and intra-arterial), [25][26][27] varying times of administration (from 4 hours to 10 days post-stroke), [28][29][30] different preclinical animal stroke models (transient, embolic, photothrombotic, and permanent occlusion), and failure to recanalize the occluded vessel. [31][32][33] Building on organized efforts to improve stroke research (such as the STAIR meetings), there have been efforts in both Europe and in the USA to apply the principles of human clinical trial design to preclinical research in order to improve rigor and translational success.…”

Section: Translational Research In Neuroprotectionmentioning

confidence: 99%

Now that the door is open: an update on ischemic stroke pharmacotherapeutics for the neurointerventionalist

Fraser

Pahwa

Maniskas

et al. 2023

J NeuroIntervent Surg

View full text Add to dashboard Cite

The last 10 years have seen a major shift in management of large vessel ischemic stroke with changes towards ever-expanding use of reperfusion therapies (intravenous thrombolysis and mechanical thrombectomy). These strategies ‘open the door’ to acute therapeutics for ischemic tissue, and we should investigate novel therapeutic approaches to enhance survival of recently reperfused brain. Key insights into new approaches have been provided through translational research models and preclinical paradigms, and through detailed research on ischemic mechanisms. Additional recent clinical trials offer exciting salvos into this new strategy of pairing reperfusion with neuroprotective therapy. This pairing strategy can be employed using drugs that have shown neuroprotective efficacy; neurointerventionalists can administer these during or immediately after reperfusion therapy. This represents a crucial moment when we emphasize reperfusion, and have the technological capability along with the clinical trial experience to lead the way in multiprong approaches to stroke treatment.

show abstract

Translating Animal Models of Ischemic Stroke to the Human Condition

Cited by 6 publications

References 68 publications

Green autofluorescence of the skin and fingernails is a novel biomarker for evaluating the risk for developing acute ischemic stroke

Green autofluorescence of the skin and fingernails is a novel biomarker for evaluating the risk for developing acute ischemic stroke

Phenomic Studies on Diseases: Potential and Challenges

Now that the door is open: an update on ischemic stroke pharmacotherapeutics for the neurointerventionalist

Contact Info

Product

Resources

About